Millendo Therapeutics Inc

NASDAQ:MLND  
1.81
+0.05 (+2.84%)
4:33:45 PM EDT: $1.79 -0.02 (-1.11%)
Other Pre-Announcement

Millendo Therapeutics Reports Q3 Loss Per Share Of $0.34

Published: 11/09/2020 13:58 GMT
Millendo Therapeutics, Inc. (MLND) - Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results.
Millendo Therapeutics Inc - Expects Its Cash, Cash Equivalents & Restricted Cash Will Support Its Current Development and Operational Plans Into 2022.
Millendo Therapeutics Inc Qtrly Net Loss per Share of Common Stock $0.34.
Millendo Therapeutics Inc - Cash, Cash Equivalents & Restricted Cash Were $43.8 Million at Sept 30, 2020, Compared to $63.5 Million at December 31, 2019.